About 12–13% of US adults have used semaglutide or another GLP-1 receptor agonist as of mid-2026. This is the highest adoption ever recorded for a prescription weight loss drug. Wegovy and Ozempic are the most popular semaglutide brands. The new Wegovy pill, launched on January 5, 2026, became the fastest GLP-1 launch in US history, surpassing 2 million prescriptions in its first four months. Total semaglutide franchise sales are projected to reach $36 billion in 2026. This article breaks down who is using semaglutide, which brands are winning, and how the market is shifting.
Key takeaways
- About 12% of US adults report ever using a GLP-1 drug; ~6% are currently using one.
- Semaglutide is the most-prescribed GLP-1 globally, with Novo Nordisk holding 55% of weekly injection market share.
- Wegovy pill prescriptions topped 200,000/week by April 2026 — the fastest GLP-1 launch ever.
- Wegovy injection sales rose 12% year-over-year in Q1 2026; Ozempic sales fell 8%.
- Wegovy commands 65% of new US GLP-1 prescriptions as of May 2026.
- Total semaglutide franchise sales projected at $36 billion globally for 2026.
- New 7.2 mg dose (Wegovy HD) launched April 7, 2026.
How many people use semaglutide in 2026?
About 12–13% of US adults have used semaglutide or another GLP-1 drug at some point. Roughly 6% are actively using one in 2026. Both numbers are climbing as Medicare and Medicaid expand coverage, the Wegovy pill makes daily oral dosing available, and new lower-cost self-pay channels reach uninsured patients.
Semaglutide adoption has scaled fast. The percentage of Americans with any GLP-1 prescription jumped from 0.87% in 2019 to 4.03% in 2024. By mid-2026, that share is on track to cross 6%. Among specific populations the numbers are much higher — 43% of US adults with type 2 diabetes report using a GLP-1 at some point, along with 22% of adults diagnosed with overweight or obesity.
| Year | US semaglutide users (est.) | Key milestone |
|---|---|---|
| 2019 | 0.9% of US adults on any GLP-1 | Ozempic in early growth phase (FDA approved 2017) |
| 2021 | ~2.5% of US adults on GLP-1 | FDA approves Wegovy for chronic weight management (June) |
| 2023 | ~6% of US adults ever used a GLP-1 | Semaglutide sales reach $13.8B in the US |
| 2024 | 4% of US adults on a GLP-1 (active use) | Wegovy gains cardiovascular risk-reduction indication |
| 2025 | ~12% of US adults ever used a GLP-1 | Wegovy pill (oral semaglutide 25 mg) FDA approved (Dec) |
| 2026 | ~13–15% projected (post-Medicare expansion) | Wegovy HD launched (Apr); Medicare GLP-1 Bridge begins July 1 |
Globally, the picture mirrors the US. Novo Nordisk now sells semaglutide in more than 55 countries. International obesity care sales grew 44% at constant exchange rates in Q1 2026 alone, with Europe/Canada up 63%, Asia-Pacific up 87%, and emerging markets up 18%. The semaglutide molecule went off patent in some international markets during 2026, opening the door for generic and second-brand versions like Poviztra and Extensior in India and Brazil.
Ready to start semaglutide treatment? Get a semaglutide prescription online, complete a quick medical consultation, and receive medication if approved. Buy semaglutide online and begin your personalized weight loss program with ongoing provider support.
Is semaglutide use growing or declining?
Overall semaglutide use is growing. The breakdown matters: weight-loss prescriptions are growing fast, while diabetes prescriptions are slipping. Between March and June 2025, semaglutide prescriptions for type 2 diabetes fell 6.4%, while semaglutide prescriptions for obesity rose 8%. The trend continued into 2026.
Three forces are driving the shift:
- New approvals and indications. Wegovy gained a cardiovascular risk-reduction indication in 2024, opening access to heart patients.
- Form expansion. The Wegovy pill (January 2026) and Wegovy HD 7.2 mg (April 2026) added oral and higher-dose options, attracting patients who avoided weekly injections or needed more weight loss.
- Medicare access. The Medicare GLP-1 Bridge program begins July 1, 2026, putting weight-loss semaglutide within reach of older Americans for the first time.
Pricing changes are also unlocking new demand. Under the “Most Favoured Nations” agreement, monthly out-of-pocket costs in the US fell from roughly $1,000 to the $245–$350 range for Medicare, Medicaid, and TrumpRx self-pay buyers. Lower prices mean more filled prescriptions.
Which semaglutide brands are the most popular?
Wegovy (in all three forms — injection, pill, and HD) is the most popular semaglutide brand in the US for new prescriptions in 2026. Wegovy now commands 65% of all new GLP-1 prescriptions, according to Novo Nordisk’s Q1 2026 earnings call. Ozempic remains the most popular semaglutide brand for type 2 diabetes treatment, though its share is shrinking as patients shift to Wegovy for weight loss.
Figure 1. Semaglutide brand share among new US prescriptions, April 2026.
Behind the headline numbers, the Wegovy pill has become the most dynamic story of 2026. Total prescriptions for the oral version reached 2 million by mid-April — only 14 weeks after launch. Weekly prescription volume hit 200,000 by week 15. Novo Nordisk’s CEO told investors the pill and injection are not cannibalizing each other but creating a “synergistic effect,” with many patients using both at different times.
Wegovy: leading brand for weight loss
Wegovy is the FDA-approved semaglutide brand for chronic weight management. The standard injection (2.4 mg weekly) remains the gold standard for measurable weight loss, averaging 14.9% body weight reduction over 68 weeks in the STEP 1 trial. Wegovy injection sales reached DKK 18.2 billion (~$2.7 billion) in Q1 2026, up 12% year over year.
Wegovy pill: the fastest GLP-1 launch in history
The Wegovy pill is oral semaglutide 25 mg, taken once daily on an empty stomach. The FDA approved it in December 2025, and Novo Nordisk launched it on January 5, 2026. It is available at more than 70,000 US pharmacies and through nine telehealth organizations. Q1 2026 sales hit DKK 2.26 billion ($354 million) — nearly double analyst forecasts.
Wegovy HD: the new high-dose option
Wegovy HD delivers 7.2 mg of semaglutide weekly. The FDA approved it on March 19, 2026, under the Commissioner’s National Priority Voucher pilot. Novo Nordisk launched it in the US on April 7, 2026. In the STEP UP trial, Wegovy HD produced 20.7% mean weight loss over 72 weeks — about 5 percentage points more than the standard 2.4 mg dose.
Ozempic: still the diabetes leader, but slipping
Ozempic remains the dominant semaglutide brand for type 2 diabetes. It is FDA-approved only for diabetes, not weight loss. Off-label weight-loss use of Ozempic dropped from 32% in 2022 to 19% in 2023 as patients shifted to Wegovy. Ozempic sales fell 8% in Q1 2026, though they still beat analyst expectations.
Rybelsus: the small but stable oral diabetes option
Rybelsus is oral semaglutide for type 2 diabetes, dosed at 3–14 mg daily. It is the smallest of the four brands by prescription volume and revenue. Rybelsus use is stable, with most patients staying on it long-term once they reach the 14 mg maintenance dose.
Semaglutide sales and market value in 2026
Total semaglutide franchise sales are projected to hit roughly $36 billion globally in 2026, up from $33 billion in 2025. The growth comes from rising prescription volumes that more than offset US price cuts. Novo Nordisk’s Q1 2026 earnings showed how individual brands are performing.
| Brand | Q1 2026 sales | YoY change |
|---|---|---|
| Wegovy injection | DKK 18.2 billion (~$2.7B) | +12% |
| Wegovy pill | DKK 2.26 billion (~$354M) | New product (launched Jan 5, 2026) |
| Ozempic | Above analyst expectations | –8% (declining) |
| Rybelsus | Stable | Flat |
| Total semaglutide (projected 2026) | ~$36 billion | +9% vs 2025 estimate |
Novo Nordisk raised its full-year 2026 outlook in May 2026 after Q1 results beat expectations. The company now expects adjusted sales to decline by 4–12% (instead of 5–13%), reflecting the strong start for the Wegovy pill and rising international demand. Stock traded up 2.07% after the announcement.
Comparing the four semaglutide brands
The four FDA-approved semaglutide brands target different needs. The table below summarizes form, approved use, and 2026 trend for each.
| Brand | Form | FDA-approved use | Trend in 2026 |
|---|---|---|---|
| Wegovy pill | Oral 25 mg daily | Weight loss | Fastest-growing |
| Wegovy injection | Subcutaneous 2.4 mg weekly | Weight loss | Strong growth (+12%) |
| Wegovy HD | Subcutaneous 7.2 mg weekly | Weight loss | New (April 2026) |
| Ozempic | Subcutaneous up to 2.0 mg weekly | Type 2 diabetes | Declining (–8% YoY) |
| Rybelsus | Oral 7–14 mg daily | Type 2 diabetes | Stable |
For weight loss, the Wegovy family (pill, injection, HD) covers nearly every patient profile. For type 2 diabetes, Ozempic and Rybelsus remain the standard choices.
Who is using semaglutide in 2026?
The typical semaglutide user is shifting. Through 2023, most users were over 65, taking Ozempic for diabetes. By 2026, a much larger share is in their 30s and 40s, using Wegovy for weight loss. About 40% of users in the nondiabetic weight-loss group are now under 45 years old.
Of the roughly 32 million US adults who qualify for semaglutide based on weight, diabetes, or cardiovascular risk:
- 45% have private insurance
- 19% have Medicare
- 13% have other state or government insurance
- 10% have Medicaid
- 13% are uninsured
Among UK users of GLP-1 drugs (a useful comparison), the average age is 44, women make up about 77% of users, and people aged 40–59 account for more than half of all prescriptions. The US pattern is shifting in the same direction — younger, more female, more weight-loss focused.
Where the semaglutide market is heading
Three forces will shape semaglutide use through the rest of 2026 and into 2027:
- Medicare GLP-1 Bridge (July 1, 2026). Part D coverage for weight-loss semaglutide will pull millions of Medicare beneficiaries into the market for the first time, at roughly $50/month copays.
- End of compounding (May 22, 2026). The FDA grace period for mass compounded semaglutide expired in May 2026. Patients who relied on cheap compounded versions are now moving to branded Wegovy or Ozempic, often through new self-pay channels.
- Oral GLP-1 competition. Eli Lilly launched its own oral GLP-1 (Foundayo) in April 2026, three months after the Wegovy pill. Foundayo is a new molecule, not a reformulation, so prescription uptake has lagged the Wegovy pill so far.
Novo Nordisk has also submitted CagriSema (a combination of semaglutide and cagrilintide) and zenagamtide (a next-generation amylin-GLP-1 dual agonist) to the FDA. Both could expand the semaglutide-adjacent market further in 2027–2028.
Conclusion
Semaglutide use in 2026 is at an all-time high and still growing. Wegovy has overtaken Ozempic as the most popular semaglutide brand by new prescriptions. The Wegovy pill is rewriting how patients access GLP-1 therapy, and Wegovy HD has set a new weight-loss ceiling. With Medicare coverage starting in July and prices falling, the semaglutide market is set for another sharp expansion through 2027.
If you are considering semaglutide for weight loss or diabetes, a licensed provider can match the right brand and dose to your medical history. Book a free consultation with Heally to get started with a semaglutide treatment plan.
FAQ
How many people use semaglutide in 2026?
About 12–13% of US adults have used a GLP-1 drug at some point, and roughly 6% are currently using one. The Wegovy pill alone reached 2 million prescriptions in its first 14 weeks on the market.
What is the most popular semaglutide brand?
Wegovy is the most popular semaglutide brand for new prescriptions in the US in 2026, capturing 65% of new GLP-1 prescriptions. Ozempic remains the most popular semaglutide brand for type 2 diabetes.
Is semaglutide use growing in 2026?
Yes. Weight-loss semaglutide use is growing fast, with the Wegovy pill driving the fastest GLP-1 launch in US history. Diabetes use of semaglutide (Ozempic) is declining slightly as patients shift to Wegovy for weight management.
How much is the semaglutide market worth in 2026?
Total global semaglutide franchise sales are projected to reach $36 billion in 2026, up from about $33 billion in 2025. The growth comes from rising prescription volumes offsetting US price cuts.
What is the difference between Ozempic, Wegovy, and Rybelsus?
All three contain semaglutide. Ozempic is an injection for type 2 diabetes. Wegovy (injection, pill, or HD) is for weight loss. Rybelsus is an oral tablet for type 2 diabetes. The active drug is identical — the difference is dose, form, and approved use.
How is the Wegovy pill different from Rybelsus?
Both are oral semaglutide. Rybelsus tops out at 14 mg daily and is FDA-approved for type 2 diabetes. The Wegovy pill goes up to 25 mg daily and is FDA-approved for chronic weight management.
Who manufactures semaglutide?
Novo Nordisk, a Danish pharmaceutical company, manufactures all FDA-approved semaglutide products: Wegovy, Wegovy pill, Wegovy HD, Ozempic, and Rybelsus. The semaglutide molecule went off patent in some international markets in 2026.
Will semaglutide get cheaper in 2026?
Yes. Under the Most Favoured Nations agreement, US semaglutide prices have fallen by up to 70% for Medicare, Medicaid, and self-pay buyers. Monthly out-of-pocket costs are now in the $245–$350 range for many patients.
Sources
- Novo Nordisk — Q1 2026 Form 6-K filing (SEC)
- CNBC — Novo Nordisk Q1 2026 earnings: Wegovy sales jump
- BioPharma Dive — Novo hikes guidance on Wegovy pill’s fast sales start
- SingleCare — Ozempic statistics 2026 (March 2026 update)
- American Journal of Managed Care — Trends in GLP-1 receptor agonist prescribing patterns
- WebMD — Semaglutide eligibility and insurance breakdown
- Drug Discovery & Development — Novo cuts GLP-1 prices 70%, semaglutide 2026 revenue analysis
Disclaimer
Market data in this article is current as of May 2026 and based on publicly available company filings, analyst reports, and industry research. Prescription estimates are approximate and may shift as new data becomes available. This article does not constitute medical or financial advice.